NO20015157D0 - Fremgangsmåte ved bestemmelse av pre-noeplastiske og/eller neoplastiske tilstander hos pattedyr - Google Patents

Fremgangsmåte ved bestemmelse av pre-noeplastiske og/eller neoplastiske tilstander hos pattedyr

Info

Publication number
NO20015157D0
NO20015157D0 NO20015157A NO20015157A NO20015157D0 NO 20015157 D0 NO20015157 D0 NO 20015157D0 NO 20015157 A NO20015157 A NO 20015157A NO 20015157 A NO20015157 A NO 20015157A NO 20015157 D0 NO20015157 D0 NO 20015157D0
Authority
NO
Norway
Prior art keywords
neoplastic
mammals
determining pre
conditions
cells
Prior art date
Application number
NO20015157A
Other languages
English (en)
Other versions
NO20015157L (no
NO331018B1 (no
Inventor
Michael Slater
Julian Barden
Original Assignee
Biosceptre Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosceptre Pty Ltd filed Critical Biosceptre Pty Ltd
Publication of NO20015157D0 publication Critical patent/NO20015157D0/no
Publication of NO20015157L publication Critical patent/NO20015157L/no
Publication of NO331018B1 publication Critical patent/NO331018B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20015157A 1999-04-21 2001-10-22 In vitro fremgangsmate ved bestemmelse av pre-neoplastiske og/eller neoplastiske tilstander hos pattedyr ved purinergisk reseptorekspresjon, samt anvendelse og sett for slik pavisning NO331018B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP9911A AUPP991199A0 (en) 1999-04-21 1999-04-21 Methods for diagnosing pre-cancerous and cancerous conditions
PCT/AU2000/000363 WO2001006259A1 (en) 1999-04-21 2000-04-26 A method for identifying pre-neoplastic and/or neoplastic states in mammals

Publications (3)

Publication Number Publication Date
NO20015157D0 true NO20015157D0 (no) 2001-10-22
NO20015157L NO20015157L (no) 2001-12-21
NO331018B1 NO331018B1 (no) 2011-09-12

Family

ID=3814111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015157A NO331018B1 (no) 1999-04-21 2001-10-22 In vitro fremgangsmate ved bestemmelse av pre-neoplastiske og/eller neoplastiske tilstander hos pattedyr ved purinergisk reseptorekspresjon, samt anvendelse og sett for slik pavisning

Country Status (15)

Country Link
US (3) US7183064B1 (no)
EP (1) EP1179183B1 (no)
JP (1) JP4633984B2 (no)
KR (1) KR100819395B1 (no)
CN (1) CN100557445C (no)
AT (1) ATE456799T1 (no)
AU (2) AUPP991199A0 (no)
CA (1) CA2371163A1 (no)
DE (1) DE60043775D1 (no)
DK (1) DK1179183T3 (no)
ES (1) ES2340137T3 (no)
HK (1) HK1044190A1 (no)
NO (1) NO331018B1 (no)
WO (1) WO2001006259A1 (no)
ZA (1) ZA200108616B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
ES2320421T3 (es) 2001-01-17 2009-05-22 Intreat Pty Limited Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones.
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
NZ583896A (en) * 2007-09-14 2011-05-27 Biosceptre Int Ltd Purinergic (p2x) receptors in extra-cellular body fluid
ES2619681T3 (es) * 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
ES2610225T3 (es) 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
WO2011020155A1 (en) 2009-08-20 2011-02-24 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
EP3321285B1 (en) 2009-12-24 2019-04-24 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação
CA2946669A1 (en) * 2014-05-02 2015-11-05 Medimmune Limited Ion channel modulators & uses thereof
JP7127021B2 (ja) 2016-10-21 2022-08-29 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 細胞傷害性粒子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) * 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JP3084982B2 (ja) * 1992-11-25 2000-09-04 富士電機株式会社 半導体装置
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
CA2228999A1 (en) * 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) * 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
JP3885177B2 (ja) * 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
ES2320421T3 (es) * 2001-01-17 2009-05-22 Intreat Pty Limited Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones.

Also Published As

Publication number Publication date
HK1044190A1 (en) 2002-10-11
NO20015157L (no) 2001-12-21
US20070248963A1 (en) 2007-10-25
WO2001006259A1 (en) 2001-01-25
ES2340137T3 (es) 2010-05-31
EP1179183A4 (en) 2003-01-22
AUPP991199A0 (en) 1999-05-13
NO331018B1 (no) 2011-09-12
AU3949000A (en) 2001-02-05
AU779845B2 (en) 2005-02-17
US20110111431A1 (en) 2011-05-12
EP1179183A1 (en) 2002-02-13
EP1179183B1 (en) 2010-01-27
JP2003504643A (ja) 2003-02-04
JP4633984B2 (ja) 2011-02-16
CN1355886A (zh) 2002-06-26
ATE456799T1 (de) 2010-02-15
ZA200108616B (en) 2002-06-13
DK1179183T3 (da) 2010-05-25
KR20020022651A (ko) 2002-03-27
CN100557445C (zh) 2009-11-04
CA2371163A1 (en) 2001-01-25
KR100819395B1 (ko) 2008-04-04
DE60043775D1 (de) 2010-03-18
US7183064B1 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
NO20015157D0 (no) Fremgangsmåte ved bestemmelse av pre-noeplastiske og/eller neoplastiske tilstander hos pattedyr
CY1111098T1 (el) Bodipy διαιθυλοακεταλη αμινοακεταλδεϋδης
NO20006681D0 (no) Fremgangsmåte ved tidlig diagnose av karsinomer
ITTO20010411A0 (it) Metodo e dispositivo per l'esecuzione di test e saggi ad alta processivita' ed alto valore biologico su cellule e/o composti.
AU2001268449A1 (en) Toxicity typing using liver stem cells
RS51903B (sr) Formulacija aripiprazol kompleksa i postupak
EP1687283A4 (en) PROCESS AND COMPOSITION FOR DETERMINING FK 506
DE59909670D1 (de) Kassette zur Förderung von Flüssigkeiten, insbesondere Dialyseflüssigkeiten
WO2003014303A3 (en) Molecular interactions in cells
AUPR201500A0 (en) Methods for identifying pre-neoplastic and neoplastic states in mammals
BR9703386A (pt) Células aviárias imortalizadas
AU1855401A (en) Screening method for candidate drugs
NO981818D0 (no) FremgangsmÕte for Õ mobilisere hematopoetiske stamceller
PT1127133E (pt) Polipeptido que proporciona permeabilidade celular
NO964803D0 (no) Fremgangsmåte for måling av konsentrasjonen av glykoler/polyglykoler i fluiden, måleinstrument samt analysesett
AU8904598A (en) Methods, kits, electrodes and compositions for assessing the level of an analyteof interest in fluid samples
WO2001071359A3 (en) Methods for identifying and isolating tissue-specific lumen-exposed molecules
WO2001004305A3 (en) Human proteins involved in detoxification
UA34205A (uk) Спосіб визначення захисної функції плаценти
ITRM20000539A0 (it) Metodo e kit diagnostici per la malattia celiaca.
WO1998015650A3 (en) Hydronephrosis gene (hng) and its use

Legal Events

Date Code Title Description
MK1K Patent expired